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Abstract
Background
Little information is known on the annual cost of ART in Ethiopia despite an increase in
scale up of ART in Ethiopia.
Methods
We examined data from 188 patient records that were on ART for one year at Zewditu
Hospital. Data on cost and utilization of ART were taken and analyzed from Zewditu
Hospital perspective. Final direct treatment cost, human resource, overhead and capital
cost were identified and internal cost comparison was done.
Result
The mean per person year total cost of treatment at out patient level was USD 342.6
including USD314 in direct treatment cost, USD19 in direct health professional cost,
USD 5 in over head and the final USD 3.03 goes to ART related capital cost. The direct
treatment cost takes a staggering 91% of the total cost. Provision of ARV takes the
highest cost of USD 210.82 followed by ART monitoring lab tests of USD90.
Conclusion
PPY cost of ART in a public sector health facility in Ethiopia is USD342.6 with ARVs
taking the largest cost share of ART cost of 62%. Further calculations revealed a total of
1 physician, 2.5 nurses, 4.5 lab technicians and 1 pharmacist are needed to treat 1000
ART clients in a public health facility.
vii
11. Introduction
In 2007 there were 2.7 million new HIV infections and 2 million HIV-related deaths. The
rate of new HIV infections has fallen in several countries, but globally these favorable
trends are at least partially offset by increases in new infections in other countries. In 14
of 17 African countries with adequate survey data, the percentage of young pregnant
women (ages 15–24) who are living with HIV has declined since 2000-2001. In 7
countries, the drop in infections has equaled or exceeded the 25% target decline for 2010
set out in the Declaration of Commitment (1, 3).
As treatment access has increased over the last ten years the annual number of AIDS
deaths has fallen. Sub-Saharan Africa remains the region most heavily affected by HIV,
accounting for 67% of all people living with HIV and for 75% of AIDS deaths in 2007.
However, some of the most worrisome increases in new infections are now occurring in
populous countries in other regions, such as Indonesia, the Russian Federation, and
various high-income countries. Globally, the percentage of women among people living
with HIV has remained stable (at 50%) for several years, although women’s share of
infections is increasing in several countries. In virtually all regions outside sub-Saharan
Africa, HIV disproportionately affects injecting drug users, men who have sex with men,
and sex workers (1)
Ethiopia is currently one of the countries most seriously affected by HIV/AIDS, with the
sixth highest number of infections in the world. To combat this epidemic, the government
of Ethiopia has  launched a national HIV/AIDS program focused on decreasing the
vulnerability of individuals and  communities to the disease, providing care and support
2for people living with HIV/AIDS, and  reducing the adverse socioeconomic
consequences of the epidemic(2).
Many African countries are rapidly expanding HIV/AIDS treatment programs. Empirical
information on the cost of delivering antiretroviral therapy (ART) for HIV/AIDS is
needed for program planning and budgeting as the existing research on HIV/AIDS focus
on the prevalence and natural history than cost(2,3).
However, annual expenditure on HIV/AIDS interventions in resource poor countries have
increased 30 times over the last ten years to an estimated 10 billion in the 2007(3).
WHO recommends that in ARV treatment programmes in resource-limited settings HIV
infected adolescents and adults should start ARV therapy when they have clinical AIDS,
regardless of CD4 count. When total lymphocyte count can be assessed, in addition
people with WHO stage II or III HIV disease should be offered treatment. When CD4
counts are available, all HIV infected people with less than 200 CD4 cells/mm3 should
be offered treatment (2).
WHO, also recommends that in resource-limited settings a single first-line regimen
should be identified for the treatment of the majority of new patients. This regimen would
consist of 2 nucleoside analogs and either a non-nucleoside or abacavir, or a protease
inhibitor. Zidovudine (ZDV)/3TC are the initial recommendation for a dual nucleoside
analog with d4T/3TC, ZDV/ddI and ddI/3TC as possible alternatives. Efavirenz and
nevirapine are recommended non-nucleosides, while recommended protease inhibitors
include ritonavir-boosted PIs (indinavir, lopinavir, saquinavir) or nelfinavir. A second
line regimen should be chosen to substitute first line regimens when needed (for toxicity
or treatment failure)(9).
3Clinical assessment prior to the initiation of ART includes documentation of past medical
history, identification of current and past HIV related illnesses, identification of co-
existing medical conditions and medications in use that may influence choice of therapy
(such as TB or pregnancy) as well as current symptoms and physical signs.
Minimum laboratory tests include an HIV antibody test, and (if ZDV is part of the
regimen) haemoglobin or hematocrit level. Highly desirable tests are white blood cell
count and differential, CD4 count, serum alanine, aspartate aminotransferase level, serum
creatinine, blood urea nitrogen, serum glucose, bilirubin, amylase and serum lipids, and
pregnancy tests for women(6).
Last, there needs to be a reliable source of financing of the services and medicines
provided. In many settings there are already some people who can provide quality
services, there is already some infrastructure that can be used, and there are already some
people who can pay for the service they need. In these settings treatment should be
offered now, while resources are sought and the health service is strengthened to do more
in the future. Today, with the increased availability of funds through the Global Fund,
PEPFAR, the World Bank and other donors, there is a considerable window of
opportunity for developing countries to scale up access to antiretroviral therapy. (3)
In order to realize universal access to free ART by 2009/2010, the Federal Ministry of
Health (MOH) is committed to decentralize further the expansion and integration of
HIV/AIDS prevention and control activities with primary health care services at
grassroots where the majority of the population lives (5).
As HIV treatment is for life, it is critical that treatment programmes be sustained for the
long term. Among the developments needed to ensure the continuity of HIV treatment are
4more affordable second- and third-line therapies, as well as greater success in preventing
new HIV infections.
Often cost analyses are an integral component of program implementations. Cost and
cost-effectiveness analyses serve to provide basic evidence for on-going policy questions
and debates.  Cost analyses have always been identified with issues of efficiency, cost
recovery and sustainability of programmes.  However, cost analysis can also play an
important role in examining issues of equity and targeting, which have recently come to
the forefront of the policy debate (11, 12, 13, 14, and 15).
Cost data are necessary prerequisite to evaluate cost effectiveness of HIV treatment in
this severely cost-constrained setting which account for the greatest share of the global
burden of HIV disease (5).
The aim of this study was, to estimate the financial and human resource cost of
providing highly active antiretroviral therapy (HAART) in a public health facility in
Addis Ababa for the first year of treatment(6)
52. Literature review
Antiretroviral therapy (ART) is extremely effective in resource poor setting increasing
survival for patients with AIDS from 30% to 90% at one year (7-10).However In
Ethiopia and the remaining African Countries there are no much published studies on
ART cost analysis based on existing programs examining the different approach for the
treatment and prevention of HIV/AIDS(5)
However a number of excel spread sheet and life time cost models have been developed
and estimated the life time cost of delivering ART. Ethiopia is one of the big recipients of
GFTAM and PEPFAR support but there are still significant proportions of PLWHA
demanding ART (3, 7).
When compared to most African countries relatively South Africa has got quite a good
experience in doing costing and cost-effectiveness analysis for HIV/AIDS interventions.
Recently WHO published a new and staggering topic called Universal testing and
immediate treatment could cut HIV infections by 95% in 10 years. The WHO model used
South Africa as an example, taking data on infection rates and disease progression to
model the effects of expanding knowledge of HIV status and a growing uptake of
antiretroviral treatment. The model assumed that with a baseline HIV prevalence of 16%,
a 99% decline in infectiousness when individuals started treatment, and 90% coverage of
treatment in the HIV-infected population by 2016, 104,000 deaths would be averted in
2015 alone when compared to starting treatment at a CD4 cell count of 350 cells/mm3 (in
itself an optimistic threshold)(16)
6The model assumed an annual treatment cost (including drugs, monitoring and patient
management) of $727 a year for first-line treatment and $3290 for second-line treatment,
with antiretroviral drugs accounting for 30% of the cost.
The model showed that HIV transmission would decline very steeply as HIV treatment
coverage expanded, falling from around 15 new infections per thousand adult and
adolescent inhabitants today to 1 per thousand by 2016.
Although the universal treatment strategy would cost three times more than treating
everyone with a CD4 cell count below 350 cells/mm3 in 2015 ($3.4 billion a year), the
yearly cost would begin to fall after this point, and by 2030 the approach would become
less expensive than treating only those with CD4 counts below 350 cells/mm3
(approximately $1.8 billion) (14).
USA experience: Health care expenditures for persons infected with human
immunodeficiency virus (HIV) in the United State determined on the basis of actual
health care use have not been reported in the era of highly active antiretroviral therapy.
Patients receiving primary care at the University of Alabama at Birmingham HIV clinic
were included in the study. All encounters (except emergency room visits) that occurred
within the University of Alabama at Birmingham Hospital System from 1 March 2000 to
1 March 2001 were analyzed. Medication expenditures were determined on the basis of
2001 average wholesale price. Hospitalization expenditures were determined on the basis
of 2001 Medicare diagnostic related group reimbursement rates(12).
Clinic expenditures were determined on the basis of 2001 Medicare current procedural
terminology reimbursement rates. Among the 635 patients, total annual expenditures for
7patients with CD4+ cell counts <50 cells/μL ($36,533 per patient) were 2.6 times greater
than total annual expenditures for patients with CD4+ cell counts 350 cells/μL ($13,885
per patient), primarily because of increased expenditures for non-antiretroviral
medication and hospitalization. Expenditures for highly active antiretroviral therapy were
relatively constant at $10,500 per patient per year across CD4+ cell count strata.
Outpatient expenditures were $1558 per patient per year; however, the clinic and
physician component of these expenditures represented only $359 per patient per year, or
2% of annual expenses. Health care expenditures for patients with HIV infection
increased substantially for those with more‐advanced disease and were driven
predominantly by medication costs (which accounted for 71%–84% of annual expenses).
Physician reimbursements, even with 100% billing and collections, are inadequate to
support the activities of most clinics providing HIV care. These findings have important
implications for the continued support of HIV treatment programs in the United
States(12).
This team sought to project the lifetime cost of medical care for human
immunodeficiency virus (HIV)-infected adults using current antiretroviral therapy (ART)
standards. Medical visits and hospitalizations for any reason were from the HIV Research
Network, a consortium of high-volume HIV primary care sites. HIV treatment drug
regimen efficacies were from clinical guidelines and published sources; data on other
drugs used were not available. In a computer simulation model, we projected HIV
medical care costs in 2004 U.S. dollars. From the time of entering HIV care, per person
projected life expectancy is 24.2 years, discounted lifetime cost is $385,200, and
undiscounted cost is $618,900 for adults who initiate ART with CD4 cell count <350/μL.
Seventy-three percent of the cost is antiretroviral medications, 13% inpatient care, 9%
8outpatient care, and 5% other HIV-related medications and laboratory costs. For patients
who initiate ART with CD4 cell count <200/μL, projected life expectancy is 22.5 years,
discounted lifetime cost is $354,100 and undiscounted cost is $567,000. Results are
sensitive to drug manufacturers' discounts, ART efficacy, and use of enfuvirtide for
salvage. If costs are discounted to the time of infection, the discounted lifetime cost is
$303,100. Effective ART regimens have substantially improved survival and have
increased the lifetime cost of HIV-related medical care in the U.S.(5)
Zambian Experience: The Zambia study analyzes the costs and resource requirements
associated with the provision of ART, VCT, several opportunistic infections and PMTCT
services. These per patient cost estimates used to project total program costs, which are
then compared to currently budgeted resources with an emphasis on financial
sustainability. The report also explores a range of policy issues including the importance
of human resource constraints; the implications of alternative monitoring protocols and
drug regimens; opportunities for resource mobilization and targeting issues. Over all the
study emphasizes ART costs rather than to propose any definitive answers (13).
Haiti Experience: the Haiti study determined direct medical costs, overhead costs, and
societal costs and personnel requirements for the provision of ART to patients with
AIDS.Data from 218 treatment naive adults were examined (20).
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3. Objective:
- To provide a comprehensive analysis of the costs and resource requirements for the
provision of ART in a public sector health facility.
3.1 Specific Objectives:
-To determine the incremental costs (direct medical costs, overhead costs, capital
cost and personnel cost) of providing ART at a public health facility from the
health facility perspective.
-To determine the initial annual per person year cost of providing ART service at
zewditu Hospital
- To compare cost components of antiretroviral therapy in a public health facility
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4. Methodology-
4.1 Design- The design was a cross-sectional record review study of treatment naïve
patients, who initiated ART at Zewditu between August, 2006-November, 2006. It
involves collection of service utilization data from patient medical records, ART
personnel, capital and overhead resources consumed and converting in to PPY year cost.
Also involves secondary data analysis of HIV/AIDS commodities and program cost from
reputable sources available locally or internationally.
4.2 The study area:
The study was conducted at zewditu Hospital. Zewditu is one of the oldest public health
facilities in Addis Ababa under Kirkos subcity. It provides patient care and opportunistic
infection treatment; PMTCT services, provider initiated counseling and testing for TB,
follow up complicated case of TB and transfer of patients to health center for DOTS and
initiate antiretroviral therapy as per the national standard. Free ART program has started
in March 2005 and since September 2005 the hospital transferred more than 1800
patients to health centers under Akaki Kaliti and Kirkos sub cities. This hospital started
the first free ART in the country in January 2005 and currently has more than 7500 active
patients on treatment. The hospital has almost the same number of clients on chronic
care. The facility also initiates ART on at least 5 new treatment naïve patients every day.
Currently the ART unit has 2 medical doctors, 3 advanced ART nurses, 5 staff nurses, 3
data clerks, 1 pharmacist, 2 druggists, 1 lab technician, six case mangers, 5 adherence
supporters and a pediatric ART physician with two nurses(9).
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Patient selection and the ART regimen at Zewditu followed national recommendations
and those set by WHO guide lines. Treatment is provided on out patient basis and with a
rare admission for critically ill patients. Referral is done in few occasions for dental and
blood transfusion.
All patients presented to ZH receive HIV Voluntary counseling and testing and screening
for other sexually transmitted diseases. All patients with cough under go evaluation for
TB. HIV positive patients have a history and physical examination by a physician and a
base line CD4 is measured. Patients with AIDS defining illness or a CD4 count less than
200 cells/ml are started on ART. Prior to starting ART, a complete blood count, renal
function tests and liver enzyme test are preformed and patients meet with nurse/social
worker for ART counseling and education.
In the hospital ART treatment protocol patients on ART are to be seen in the clinic
weekly for the first two month of therapy and then monthly there after. At each visit
patients are seen by a clinician (physician or nurse) and by a pharmacist who dispense
ARV and provides adherence counseling.
Laboratory monitoring includes CD4 counts, liver function tests, renal and glucose tests
and complete blood counts. If an opportunistic infection is suspected, appropriate
laboratory testing is performed. TB medication are prescribed in the ART clinic and
dispensed in the TB clinic setting.
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4.3 Sample Size-
The purpose of the study is to estimate the mean initial annual cost of ART at Zewditu
Hospital.
Sample size (n) =z2sd2/w2
Where Z =1.96 at 95% CI
SD= standard deviation
In a cost study made in Arbaminch hospital they estimated the service use and mean
annual cost of care from 58 patients on ART. Using this sample size they obtained mean
annual cost of US$ 235.44(218.11-252.78). The following calculation is done to get the
standard deviation.
So that    34/2=1.96 s/square root of n. 34/2=1.96*S/7.5
17*7.5=1.96*S
S=130/1.96=64
D=9.1(assumed to be the marginal error, equivalent to 1 USD at the September, 2006) the
sample size for this study was N=Z2S2/d2=1.962642/9.12
= 3.84*4096/83=188
4.4 Sampling: Out of the 5000 clients on ART at Zewditu Hospital only those previously
treatment naïve clients started ART at Zewditu Hospital in the last one and half year was
considered for this protocol. Patients lost to follow-up and pediatric clients less than 12
years will be excluded from the research.188 patients were selected based on
convenience to ensure that each patient is treatment naïve when he/she started treatment
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4.5 Inclusion Criteria:
Medical records of All adult ART clients greater than 12 years who were treatment naïve
during ART initiation and currently active were eligible for the research. The patients
should at least continued taking ART services at this Hospital for a year.
4.6 Exclusion Criteria:
Patients transferred from other facilities to Zewditu after previously taking ART at any
other health facility were not considered. Also patients that didn’t complete or lost to
follow-up before the first year treatment are excluded. Pediatric clients less than 12 years
and adult clients lost follow-up with less than a year on treatment are excluded.
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4.7 Data collection-
4.7.1 Cost data.
Costing was done from Zewditu Hospital perspective and included out patient costs using
a bottom up approach in which each component of health care that is consumed is
recoded and multiplied by a unit cost. Using a bottom-up costing [6] approach, individual
cost components were identified, estimated and/or calculated on a per-patient basis as
accurately as possible. These costs were then aggregated, yielding a total per-patient year
cost.
Actual health care services utilization was determined from consecutively enrolled
treatment naïve adult AIDS patients who initiated ART at Zewditu hospital from
September 1, 2006-November 30, 2006. For each patient age, weight, WHO clinical
stage, OI illnesses, laboratory and radiographic tests conducted, ARV medications and
number of pills dispensed, medications for OI,TB were collected and entered in to EPI
info.
Service utilization and costs were estimated for direct out patient ART service utilization,
direct health labor, direct capital (building and equipment) and recurrent inputs for final
HIV care and treatment services; other shares from the hospital overhead costs were also
included as an ingredient to the total cost.
Direct health services include consultations at the HIV clinic, laboratory tests, imaging,
and drug dispensing.
Due to the unavailability of capital cost estimation, the economic cost of building based
on the market renting price was used for the building and the replacement cost for the
medical equipments.
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A combination of data collection tools were used for the collection of quantitative data.
This included a data collection tool from the medical records (annex2) and an ART
costing based on the cost of products when they are availed in Ethiopia. A tool for
collecting data from the patient medical records is developed and available in the annex
part. Using this tool we extracted weight, diagnosis, laboratory and radiographic tests
conducted and other investigations, ART medications and number of pills dispensed,
medications for TB, and Opportunistic infections, referral to higher level care and
hospitalization.
Through out this study costs were measured in 2006 US dollar, 1 USD= 9.1 ETB(18),the
cost of ARVs,OI drugs , other medications and lab reagents were obtained from the
national quantification report. Costs for TB drugs were obtained from the WHO cost for
full DOTS for six months.
The cost of laboratory tests that were not available on the national quantification was
obtained internally from Zewditu Hospital accounting.
To determine labor cost in the ART clinic an time motion observational study and an
interview was conducted on the average time needed to consult and diagnose a patient.
The pharmacist was interviewed on the estimate of time needed to dispense ARVs and OI
drugs to the client. To reduce observation bias measurements were conducted from the
waiting room at unannounced dates and times. To determine the lab personnel labor we
used the estimation of the lab technician for the time the machines take to give results. A
fair estimate for sample taking and patient preparation was included in to the time taken
by the machine to run multiple tests at a time.
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To estimate this indirect labor cost it is assumed that for every direct minute of health
professional 50%, i.e. 30 seconds for each health professional minute. Indirect labor cost
for the administrative staffs is assumed as 50% of the face to face time spent.
4.8 Data Analysis:
Patient related data were entered to epiInfo and then exported to SPSS for analysis. The
primary outcome was base line characteristics. Service utilizations were presented as
mean and median with mean cost (see Tables 1 and 2). For primary outcomes, univariate
analyses were conducted using the following variables: Base line CD4 cell count, age,
sex. WHO clinical stage, ARV regimen, and baseline weight.
The final expected out come of this study was cost of management for one year. Direct
cost was approximated by the use of out patient based ART care services presented as
mean and median costs with inter quartile ranges.
Secondary out comes included physician, pharmacist, nurse, lab technician and counselor
time. Overhead and capital costs were calculated from the facility records.
4.9 Data Quality
Data were collected by the head nurse of the ART clinic from the patient records and
closely supervised by the PI .Data entry; cleaning and analysis were done exclusively by
the PI with technical support of ACIPH statisticians. Measures were taken when there are
occasions that could affect the data quality.
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4.10 Ethical consideration
Ethical clearance was obtained from the ACIPH/UoG ethical committee and informed
consent was obtained from Zewditu Hospital staffs that were observed. The data
collection tool doesn’t require the name of the patient. All information is collected from
the patient folder using folder number.
4.11 Operational definitions
4.11.1 Direct cost of ART
Direct cost of ART is the total value of the resources expended by Zewditu Hospital in
delivering ART to the patient directly. This study’s direct cost identified in terms of
direct service utilization (lab, ARVs, OIs, other medications and professionals directly
involved)
4.11.2 Over head costs
Overhead are costs which are used by the ART clinic and shared by other services too.
4.11.3 Capital costs
Capital costs are the cost of building and equipments or machines consumed/used by the
ART clinic.
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5. Results
5.1 Base line characteristics of patients sampled for Costing record review (n=188)
The details of various baseline characteristics of the patients are summarized in table
1.The records reviewed consists of 188 treatment naïve patients initiated ART at Zewditu
Hospital between September-November,2006.
Table 1: Base line characteristics of patients sampled for Costing record review
Characteristics Number Percent
Sex Male 79 42
Female 109 58
Age 12-20 year 2 1.1
21-30 year 77 41.4
31-40 year 60 32.3
41- 50 year 34 18.3
> 50 year 13 7.0
Initial
ART
regimen
ZDV/3TC/NVP 62 29.87
D4T/3TC/NVP 66 31.73
ZDV/3TC/EFV 38 18.27
D4T/3TC/EFV 36 17.30
Other Regimens 6 2.83
Baseline
CD4
<50 25 14.4
50-199 120 69
>199 29 16.7
WHO
clinical
stage
Stage I 2 1.1
Stage II 37 19.7
Stage III 91 48.4
Stage IV 57 30.3
Female treatment recipients constitute 58% of the total clients now on treatment are more
frequent than the male.
Age range of 21-40 constitute almost 3/4th of the total clients on treatment where as 2 and
13 patients were recorded as under 20 and over 50 respectively.
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All the four first line regimens were observed with small percentage going to non first
line regimens in the first year of treatment. Nevirapine based regimen constitute almost
65% of the total patients on treatment which is in line with the national guide line
(16).Few regimens containing Tenofovir are reported from Zewditu Hospital. The total
regime was greater than the total patients sampled because of shift within the guide line
(5). Regimen shift to new drugs were also observed in 2.83% of patients on treatment
which results due to adverse drug reaction and failure to improve after initiation (5)
Most patients analyzed fall to the 51-199 CD4 counts which fairly supports the national
assumption. 14 patients initiated ART with out base line CD4 either due to machine
failure or stock out of test kits.
The Stage three constitute almost 50% of the total clients on ART while stage one is the
list. Patients with CD4 count more than 200 were put on treatment due to clinical
progression of disease showing specific stage IV illnesses. In the health facility staging is
done based on either cd4 count or clinical symptoms that show disease progression.
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5.2 Direct Treatment Utilization and cost for the total records reviewed
For the successful use of ARVs there should be access to specific services and facilities:
HIV counseling and testing and follow-up counseling services to ensure psychosocial
support and adherence to treatment; Capacity to appropriately manage HIV related illness
and opportunistic infections; A laboratory that provides tests for monitoring treatment; A
continuous supply of antiretroviral and medicines for the treatment of opportunistic
infections and other HIV related illnesses; In addition, there is a need for adequately
trained doctors, clinical officers, nurses, laboratory technicians, pharmacists, counselors
and clerks to provide the services required.
The actual health care services utilization for the first year of treatment was determined
from 188 consecutively enrolled treatment naïve patients at Zewditu Hospital from
September 1, 2006 to November 30, 2006. Costs were determined from Zewditu hospital
perspective and included all costs for pre-ART and the next 12 months after ART
initiation. The unit cost per test for lab include cost for reagent, consumables like
syringes, pipettes, gloves, specimen slides, lancets and running cost added based on an
expert opinion. Together these yielded the total unit cost for materials per test. Estimation
of lab building cost for Zewditu is a difficult task as the building is serving beyond its
estimated age and no clue about initial cost. Calculating the economic cost per square
meter based on the market price has been the best alternative and this was treated with
other capital items in table 5.
The unit cost for ARV and OI drugs per patient include the cost plus 10% for domestic
clearance, storage and distribution. The original cost is taken from the national
HIV/AIDS commodities quantification report (25).
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Cost for xray is taken from Zewditu hospital a client paying for a single chest xray the
same applies for AFB.
Table 2: Direct treatment utilization and costs for the total records reviewed
(n=188)
Mean utilization
per patient for the
1st year of ART
Median utilization
(IQ range) per
patient for the year
of ART
Mean cost per
patient for the
1st year of
ART (USD)
Clinical chemistry(
mean # of tests)
4.55 5 ( 3 to 6) 34.94
CD4 cell count
(mean # of tests)
2.09 2  (2 to 2) 20.27
Hematology( mean #
of tests)
4.88 5 (4 to 6) 32
TB tests/AFB (mean
# of tests)
1.16 1 (1 to 1) 1.16
HCG(mean # of
tests)
1.07 1 (1 to 1) 1.07
Stool (mean # of
tests)
1.51 1 ( 1 to 2) .5
Other laboratory
tests(mean # of tests)
1.09 1 (1 to 1) 1
Total Lab and
imaging
90.94
Chest radiographs (
mean # of x-rays)
1.21 1(1 to 1) 1.78
D4T/3TC/NVP(mean
# number of tablets)
689.11 720 (720 to 720) 29.20
D4T/3TC/EFV(mean
# of tablets)
684.61 720 (720 to 720) 37.50
ZDV/3TC/NVP(
mean # of tablets)
661.96 720 (720 to 720) 80.82
ZDV/3TC/EFV(mean
# of tablets)
684.61 720  (720 to 720) 52.86
Other regimens(
mean # of tablets)
720 720(720 to 720) 10.44
Total Antiretroviral
Drugs
210.82
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TB medication (mean
# number of days on
therapy)
42 0(0 to 0) 2.57
Cotrimoxazole( mean
#  of tablets)
362.98 360(360 to 360) 7.50
FANSIDAR( mean #
if tablets)
3.7 0(0 to 0) 0.3
ACYCLOVIR(mean
# of tablets)
4.90 0(0 to 0) 0.1
Dactrin Oral Jel(
mean # of tablets)
0.3 0(0 to 0) 1
Fluconazole(mean #
of tablets)
18 0(0 to 0) 0.7
Other medications(
mean # of tablets)
28.81 0(0 to 0) 0.5
Total TB,OI and
other medications
12.67
Fig 2: Total PPY Direct treatment cost.
TOTAL DIRECT TREATMENT COST
Total Lab and
Imaging (5%)
Total
Antiretroviral
Drugs (66%)
Total TB, OI and
Other
Medications (29%)
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This figure indicates the major cost proportions with antiretroviral drugs constituting
66% antiretroviral drugs. Lab and imaging come second while other non-ARV drugs take
little proportion.
5.3 Direct Health Professional Cost
From observation conducted it is found that on average a physician spend 10minutes and
nurses spend 20 minutes per single visit. For an MD level work which is diagnosis and
consultation an average number of minutes spent per patient during baseline, ART
initiation and monitoring and ART continuation phase visits for one year were converted
in to weighted salary per minute. This weighted salary per minute on clinical activity per
patient was used to convert the minutes in to birr and then dollars. These values then used
to calculate the final cost on clinical activity the same was applied for lab and pharmacy.
For out patient care ,number of visits is the unit of out put, this total out put must be
divided by the total inputs(time) to get the unit cost of per visit(15).A time motion
observation approach was followed for ART clinic, pharmacy and lab.
It should be noted here that public sector health workers have on average the following
days of leave each year: 35 days vacation; 20 days for sickness; 13 public holidays; and
12 days for mother’s leave (females only). Based on 260 week days/year, the average
number of days worked each year by one worker is 180. It is assumed that in each eight-
hour day, a worker is actively providing client  service for six hours and that two hours
are for other work, such as staff meetings, logistics management, or waiting time(6).
As the ART clinic, lab and pharmacy are organized for the unit separately from other
services all professional staffs spend 100% of their time serving ART and pre ART
clients at the clinic. Based on the monthly salary for the various staffs and assuming 1600
working hours per year and the total time worked per month come up with the weighted
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salary per minute. So the mean total physician time 1.67 hours per patient per year and 4
nurse hours per patient per year. By the same token it takes 7.16 lab technician hours and
1 pharmacy technician hours per patient per year. It is assumed that each full time
professional will work 1600 hours per year.
Table 3: Labor cost to the ART clinic, lab and pharmacy personnel
Average
number of
Minutes per
visit
Total number
of visits for
both ART and
pre-ART
work up
Total
minutes per
year
Salary ppy
(USD)
Doctor time in min(
Diagnosis and
consultation) per visit
10 10 100 4.29
Nurse time(for
Adherence  counseling)
per visit
20 12 240 4.94
Lab technician 86 5 430 8.85
Pharmacist/pharmacy
technician time per visit
10 6 60 1.64
Total 19.72
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Fig 3: Total direct health professional cost.
The pie diagram compares Lab technician time take 45% of the labor cost contribution to
ART with nurse time coming second. Physician time and pharmacy professional time
take third and fourth place respectively.
Lab technician
45%
Pharmacist/pha
rmacy tech
8%
Nurse cost (for
Counseling) per
Visit
25%
Doctor cost (
Diagnosis and
Consultation)
22%
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5.4 ART Related Overhead Cost
ART related over head is estimated the ART services percentage when compared to other
clients which represent around 20% of the total hospital clients.
The largest over head cost goes to data a clerk which is due to high number data
processing activities in all of the units. Routine recording and reporting at the clinics,
pharmacy and lab for program monitoring and evaluation and intervention as required.
Re-supply of commodities to health facilities is done based on consumption reports sent
to medical store. Activities like HMIS and DMIS proved to be very important in decision
making and program monitoring.
Table 4: ART related overhead cost analysis
Over head cost Mean cost per patient par
year(USD)
Non-direct patient care time for a health
professional(Medical director)
.15
Labor for administrative staff .03
Electricity .03
Data clerks 0.96
Security -
Telephone 0.54
Internet 0.48
Cleaning supplies 1
Stationery supplies 1
HMIS .36
DMIS .90
Lab log books .03
Total over head cost per patient per
year
5.48
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Total ART related overhead
0.54
0.48
1
1
0.36
0.9
0.03
0 0.2 0.4 0.6 0.8 1 1.2
telephone
internet
Cleaning supplies
Stationery supplies
HMIS
DMIS
Lab log books
Fig 4: Total ART related overhead cost plotted in a bar graph where Y axis represents
areas and X axis represent cost in USD.
5.5 ART related capital cost
Given the building is very old and no capital cost allocation available, the economic cost
is used assuming what would be the rental fee per square meter of the floor.
The facility a total of 200metersquare is allocated for the clinic, lab and pharmacy. Based
on my interview with the owners of shop around it costs up to 50 birr per square meter in
the locality to get a space for business. The total area used was converted in to cost using
the market value of 50birr/sqm and divided to the total number of clients served at the
facility that base year. At the end of August, 2006 there were 3479 ART clients on ART
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as stated on the monthly ART uptake report of August, 2006 [17].The average cost of the
different chemistry, hematology and CD4 machine is USD 2000 with assumption of 5
years live span. Most other equipments have less than one year shelf life so excluded
from the capital cost.
Table 5: ART related capital cost analysis
Building/as economic cost of per square
meter
Cost in USD
0.87
ART clinic computers and furniture 0.1
Lab equipments(cd4,hematology,chemistry
machines
2.06
Transportation and storage of medication
and equipment
0.04
Total 3.03
For all the exchange rates 1usd=9.1ETB
Fig 4: ART related capital cost.
With aging building and low economic cost assumption the lab machines take the major
capital cost at Zewditu Hospital.
capital cost
Building
28%
computers and
furniture
3%
Lab equipments
68%
Transportation
and storage of
medication
equipment
1%
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5.6 Over all Cost Finding
The mean total cost of out patient treatment was USD 342.66 Table 6 presents this value
PPY. This includes 314.43 as direct treatment cost, USD 19.72 direct health professional
cost, USD 5.48 over head cost and USD 3.03 for capital cost.
Table 1 shows the mean direct cost per patient per year which is USD 210.82 for ARV
the largest when compared with the group and the remaining health professional, indirect
,overhead and  capital cost, USD 90.94 for labs and related diagnostics, USD 12.67 for
other medication including OI drugs and TB drugs.
PPY cost of USD 19.72 was spent as a direct health professional cost which is directly
related to personnel spending 100 % of their time at the ART clinic, ART pharmacy and
ART lab units.
The over head cost was 5.48 the largest of which is the cost for data managers Table 3.
The capital cost PPY was USD 3.03 the largest of which is the depreciation cost for the
ART lab equipments as seen in table 4.
Table 6: Total Annual cost of ART at Zewditu Hospital PPY
Direct treatment cost PPY
Overall cost in
USD
Percent (%)
314.43 91.7
Direct health professional labor cost PPY 19.72 5.7
Total overhead PPY 5.48 1.6
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ART related capital cost PPY 3.03 1
342.66 100%
Toral cost of ART
 treatment cost
91%
 professional
labor  6%
overhead  2%
capital cost
1%
Fig 5: Total PPY cost of ART at Zewditu Hospital,
As can be seen from this pie diagram the largest cost goes to direct treatment or service
utilization costs at the ART clinic
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6. Discussion
This study determined direct medical costs, overhead, capital and direct health
professional cost of providing ART in a public sector health facility for the first year.The
major services driving the cost of ART in Zewditu hospital are direct health care services
of ARV drugs,lab monitoring and OI drugs comprising of 91% of the total cost.
In Zewditu Hospital patients take ARVs for an average cost of USD 210.82 for a three
drug combination per year. This means ARV can be made available for less than a dollar
per day in Ethiopia. With the decreasing cost of ARV drugs and fixed dose combinations
made available recently (31) still ARV cost consumed up to two third of the PPY cost of
ART in Zewditu Hospital.
Lab tests for monitoring response and toxicity detection cost an average cost or USD91
which is around a quarter of the total cost of ART in Zewditu Hospital by consuming
USD91.
OI drugs and other drugs dispensed in relation to HIV take around USD12,cotrimoxazole
is take almost 60%  of the total dollar spent on OI drugs which is due to the fact that all
patients will take cotrimoxazole as a prophylaxis  daily for the first year of treatment.
The unit PPY ART cost USD 342.66  of this study obtained for out patient ART cost was
greater than that of reported by the Arbaminch Hospital (16) but less than that of South
Africa (18) and Haiti (19).With the gradual reduction in ARV price now made available
for less than USD 100 PPY for D4T based regimens (20).When the lab monitoring cost is
compared with that of the Arbaminch Hospital Study (10) and Haiti study (13) our study
has a higher CD4 test utilization rate which could result from a recent support by
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PEPFAR on procurement of lab and other diagnostic supplies. When compared with the
Haiti Study (13) USD 355 for ARV, lab and imaging USD 130, direct health professional
labor USD 51, non ARV medications USD 39 is greater than our estimation which could
result due to less associated direct cost and the use of generic supplies.
Our mean labor cost for PPY out patient visit of USD 19.72 table 3 was greater than that
of Haiti (19).This was mainly due to the higher number of out patient visits observed at
ZH with more nurse and lab encounter than the Haiti team. More CD4 tests were done
2.09 PPY than 1.3(19) in Haiti which could contribute for the higher number of hours
spent on ART client bay a lab technicians.
This facility runs with far less number of health professionals than this model and other
studies indicated (12-15).With high client burden on treatment and chronic care in the
facility additional staffs could hasten ART scale up.
Several studies have been done to address the cost of ART (10-21) using different
scenario and assumption. In a recent study done by Demissie et al, it is reported that an
annual cost of USD 235 is required to provide ART at an out patient setting (17).Data
from sub-Saharan Africa by Bertozi et al (18) reported a per person year cost of US538.a
study from South Africa (18) stated that the cost of ART decreased compared with a non-
ART condition. A recent report from Haiti suggested that ART costs approximately USD
1000 PPY of which 36% goes to the cost of ARV (20).The cost per year of healthy life
gained would be only 8776 to USD 13902 for triple combination therapy if they worked,
even before cost saving due to prevented income losses and avoided medical cost are
considered (11).
From a Boston university study in 2006 (21), 17 eligible cost estimates were found. Of
these, 10 were from South Africa. The cost per patient per year ranged from $396 to
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$2,761. It averaged approximately $850/patient/year in countries outside South Africa
and $1,700/patient/year in South Africa. The most recent estimates for South Africa
averaged $1,200/patient/year. Specific cost items included in the average cost per patient
per year varied, making comparison across studies problematic. All estimates included
the cost of antiretroviral drugs and laboratory tests, but many excluded the cost of
inpatient care, treatment of opportunistic infections, and/or clinic infrastructure.
Antiretroviral drugs comprised an average of one third of the cost of treatment in South
Africa and one half to three quarters of the cost in other countries which is in favor of this
study finding in Zewditu Hospital. This finding is out side the range of this study because
of a rapid decrease of cost of ARV and related services (22).
In a WHO sponsored study (21), Depending on the treatment regimen used, the price of
first-line medication has decreased between 37% and 53% in the past two years. This has
contributed significantly to wider availability of treatment, but prices remain
unacceptably high in some countries, especially for second-line regimens. In 2005, the
average price paid for first-line treatment (prequalified by WHO) in low-income
countries ranged from US$ 148 per person per year for the fixed-dose combination of
stavudine + lamivudine + nevirapine (the most widely used combination) to US$ 549 for
the fixed-dose combination zidovudine + lamivudine plus a single dose of efavirenz . The
average price of these two combinations was US$ 268 per person per year in 2005.The
fall in drug prices between 2003 and 2005 has been fuelled by the ongoing scale-up of
treatment programmes as well as by increased competition among a growing number of
products prequalified by WHO. The price decrease is also attributable to negotiations
between the William J. Clinton Foundation and major generic manufacturers (17).
35
From the direct treatment cost ARV takes the lions share with 66% percent and when the
direct cost is compared with the remaining cost centers it took 91% percent of the total
expenditure (Table 6). The cost of ARV of this study was less than that of the Haiti (19)
and South Africa (18). Most studies show that the major cost goes to direct cost of
ARV,lab monitoring ,OI drugs and direct health personnel costs (10, 11, 12, 13,14, and
15).
On the other hand, ART has had a major impact on the health of people living with
HIV/AIDS. However it does mean that large numbers of people now need to have regular
checks at hospitals clinics for monitoring of drug-side effects and disease progression, for
repeat drug prescriptions, and other care (26).
The major hurdle for health services in sustaining the provision of long-term care for
people living with HIV, and scaling-up treatment services further, is the severe shortage
of doctors and nurses. This has reached a crises point in most African countries.
Maintaining regular clinic follow-up is also a major challenge for patients on ART
because of the high cost and limited availability of transport. Research in Jinja district,
Uganda, shows that the average cost of accessing treatment (mostly transport to the
clinic) is around 13-20% of patients’ monthly income. In most countries, ART services
are delivered through hospitals which serve large populations and are located in urban
areas. This has the advantage that patients can be treated by specialist clinical staff.
However, there are considerable draw-backs. Given the scale of the need for ART and the
severe shortage of clinical staff, especially doctors, demand for these services far exceeds
the capacity of hospitals. From the patients’ perspective, getting transport from rural and
semi-urban areas to a hospital is often difficult and prohibitively expensive, meaning
many are unable to access ART. In addition, centralized clinics are often overcrowded
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and waiting times are long. To what extent HIV management needs to be done at clinic
by doctors and nurses is not clear. WHO recommend decentralized service delivery and
use of lower level health-care workers to increase access to ART, but the evidence-base
for this strategy is limited (20).
In summary ART cost USD342.66 in Zewditu Hospital for the first year of treatment
with three drug combination ARV dugs taking 61% of the total cost.Further analysis
showed that to treat 1000 cleints in Zewditu Hospital  a human resource of 1
physicain,1pharmacist,2.5nurses and 4.5 lab technicians.
6.2 Strength of the Study
1. It depicts a PPY cost analysis of ART from the health facility perspective which
indicates the total cost of ART. As the contribution from user fee is minimal or
non-existent.
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2. Costs were compared with each other so that they enable program managers to
now the most expensive components and helps in priority setting.
3. The study was conducted in a public health facility in the heart of Addis where
there is an optimum ART care by Ethiopian standard and the facility has
similarity with most of the public sector setting in Ethiopia.
6.3 Limitations
1. Time and resource constraint limited this study to a public sector health facility as
treatment costs and human resource demands will likely vary from facility to
facility.
2. Because of time constraint only few observations were made for the time motion
study of ART clinic, lab and pharmacy staffs.
3. An availability of capital cost forced us to use economic cost of buildings in the
vicinity.
4. Including pediatric and lost follow-up clients would have added some other
dimension to this study.
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7. Conclusion and Recommendations
The analysis indicates that the highest cost is associated with direct treatment cost. High
costs are associated with antiretroviral drugs followed by treatment monitoring lab tests.
In a public sector health facility on average USD 340.64 at 95% CI must be spent at an
out patient level to keep a single patient for the first year on treatment.
Further calculations revealed a total of 1 physician, 2.5 nurses, 4.5 lab technicians and 1
pharmacist are needed to treat 1000 ART clients in a public health facility.
This could help as a tool for estimating resource requirement to provide ART at public
health facility in Ethiopia.  Further cost studies must be done specially in the private
sector and pediatric patients to consolidate this finding. The implication of this finding
goes beyond Zewditu Hospital as the facility is similar to most other in the country.
As there is a huge demand for ART and only half of the universal access target is reached
by this time, cost analysis is a good tool to understand the resource requirement and
subsequent service expansion (10-22).
Our study of cost estimates if supported with studies in the private sector could help in
the implementation of ART in Ethiopia if augmented with further studies in private sector
and training hospitals with a specialized care.
This study can help as entry point for further cost effectiveness analysis of ART program
in Ethiopia.
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9. Appendix
Annex 1
Consent form
Dear Respondent
My Name is Shimelis Endailalu. I am a master of public health student at Addis
Continental Institute of Public health and University of Gondar. I have permission from
the Hospital to interview you and get information and estimate the mean annual cost of
ART at Zewditu Hospital. Any information you give me is confidential and It is not
going to be shared to no one else except the research team without mentioning any thing
about you. All your responses are very useful for the study and any time you don’t want
to respond, your right not to is totally maintained
I thank you in advance for taking a time with me.
Do you agree to interview? Yes___ No ____
Name of Interviewer:         _______________________
Date of interview: ________________________
Code:                                  ________________________
Time started:                       ________________________
Time ended:                        _______________________
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Annex 2: Data Sheet For the costing of HIV/AIDS at Zewditu Hospital
1. Folder Number                                                      (Patient will remain anonymous)
2. Date ……. /……/……..
3. Patient on treatment           transferred              lost to follow up
4. Demographic information Sex               age:           Weight
5. Department : Pads           Medicine        Gynecology          Obstetrics         Surgeon
6. In-patient day         (e.g. Day 1,Day 2, etc)
7. Ordinary Hospital bed            / ICU         /High care unit
8. HIV/ADIS related disease diagnosis and complications
Diagnosis
a) c)
b) d)
9. Describe the patient according to W.H.O Clinical Staging Criteria  1         2
3          4
10. Procedures done only in relation to HIV/ADIS illness or complication (please tick
-)
Pleural tap Neb Mask IV drip line                      ECG
Lumber Puncture Biopsy Oxygen (FMO2
Bronchoscopy                  Sigmidoscopy                 Naso-gastic tube ICD inserted
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Other                          Specify: …………………………………………………..
11. Consumable used only in relation to HIV/AIDS illness or compilation(the total
amount used daily for each item) Please Check consumable list
a)…………………………………………
d)……………………………………………
b)…………………………………………
e)……………………………………………
c)…………………………………………
f)……………………………………………
12. Laboratory service, and blood product used in relation to HIV/ADIS illness or
complication. Please check laboratory service.
a)…………………………………………
e)……………………………………………
b)…………………………………………
f)……………………………………………
c)…………………………………………
g)……………………………………………
d)…………………………………………
h)……………………………………………
13. Radiology
Only in relation to HIV/ADIS illness or complication
Sonar CT X-Ray Nuclear Med
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Specify:
…………………………………………………………………………………….
14. Theater: Only in relation to HIV/ADIS illness  or complication
Yes                        No
Description: ………………………………………………….Hours:
15. Doctor : Note down approximately how much time was spend with the patient
examining ,doing procedure and other tasks:
Less than 15 min                          15 min                            30 min
45 min 60 min                           more than 60 min
16. Received counseling from social worker/nurse: only in relation to HIV/ADIS
illness or complication
Yes                        No
17. Received Physiotherapy only in relation to HIV/ADIS illness or complication
Yes                        No
18. Miscellaneous : Only in relation to HIV/ADIS  illness or complication
Specify: ……………………………………………………….
19. Any Prophylactic treatment given?   Yes No
Example: Co-trimoxazole   or INH Specify: …………………………………
20. Is the Patient on TB treatment?    Yes                No                 (if yes Please specify
under 22)
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21. Is the patient on Anti-retroviral treatment?  Yes           No         (if yes Please
specify under 22)
22. Medication:Only in relation to HIV/ADIS illness or complications
Please tick where appropriate
a) Discharge medication, please note total amount as dispensed by our
Pharmacy. Applicable only at last day of stay.
b) In patient Medication .Please note total amount per day as dispensed
by your Pharmacy.
Name of Medication Dosage PO/IV/IMI Total
amount
23. Is patient referred to higher level for illness related to HIV/AIDS?  Yes           No
Specify the reason if the answer is yes? --------------------------------------
Annex 3: Antiretroviral drugs costing tool
Sr. Product Unit
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No. price
1 Abacavir 20mg/ml, 240ml
2 Abacavir 300mg, 60 tabs
3 Didanosine 100mg, 60 tabs
4 Didanosine 250mg, 30caps
5 Didanosine 25mg, 60 tabs
6 Didanosine 2g powder
7 Didanosine 400mg,30 caps
8 Efavirenz 200mg, 90 caps
9 Efavirenz 30mg/ml, 180ml
10 Efavirenz 50mg, 30 caps
11 Efavirenz 600mg, 30 tabs
12 Indinavir 400mg, 180 tabs
13 Lamivudine 10mg/ml,240ml
14 Lamivudine 150mg, 60 tabs
15 Lopinavir/r, 166mg, 180 caps
16 Lopinavir/r, 80/20mg/ml, 300ml
17 Lopinavir/ritonavir,(200+50) Tablet of 120
18 Nelfinavir 250mg, 270 caps
19 Nevirapine 10mg/ml, 240 ml
20 Nevirapine 200mg,60 tabs
21 Ritonavir 100mg capsule of 336 capsules
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22 Stavudine 12mg/Lamivudine 60mg of 60
23
Stavudine 12mg/Lamivudine 60mg/Nevirapine
100mg of 60
24 Stavudine 15mg, 60 caps
25 Stavudine 1mg/ml, 200ml
26 Stavudine 20mg, 60 caps
27 Stavudine 30mg, 60 caps
28 Stavudine 40mg,60 caps
29 Stavudine 30mg/Lamivudine 150mg of 60
30
Stavudine 30mg/Lamivudine 150mg/Nevirapine
200mg of 60
31 Stavudine 6mg/Lamivudine 30mg of 60
32
Stavudine 6mg/Lamivudine 30mg/Nevirapine
50mg of 60
33 Tenofovir 300mg, 30 tabs
34 Zidovudine 100mg, 100 caps
35 Zidovudine 10mg/ml, 100ml
36 Zidovudine 10mg/ml, 240ml
37 Zidovudine 300mg, 60 tabs
38
Zidovudine 300mg/Lamivudine 150mg/Nevirapine
200mg of 60
39 Zidovudine/Lamivudine 450mg, 60 tabs
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Annex 4: ART lab monitoring commodities and rapid test kits costing tool
Item Description Unit price
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HIV rapid tests
Screening Determine
Confirmatory Capillus
Tie-Breaker Unigold
CD4 reagents
CD4 reagent kits (Double  tube)
CD4 control kits
FACSflow
FACSclean
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FACSrinse
Thermal paper for FACS Count
Tru Count Tubes w/ monoclonal
Facs Lysing
FACS Calibrite 3 -25 tests
Chemistry
ALP
Alpha-amylase
Bilirubin - direct
Bilirubin - total
BUN
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Cholesterol
Creatinine
Glucose
GOT (AST)
GPT (ALT)
Triglycerides
Chemistry multi-calibrator
Control, normal
Control, pathological
Haematology
Cell-Dyn detergent solution
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Cell-Dyn isotonic diluent
CN-free HGB/WIC (diff) lyse
Cell-Dyn enzymatic clean
Cell-Dyn calibrator
Cell-Dyn trilevel control
Consumables
Glove, latex disposable, large
Glove, latex disposable, medium
Glove, latex disposable, small
Pasteur pipette, 3ml
Vacutainer tube, EDTA 5 mL
54
(purple top)
Vacutainer needle, 21 G
Vacutainer tubes, plain/red-top, 10ml
Annex 5:
Other Consumable supplies
Item Description Unit price
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Consumable items
Blood Lancent of 100/pack
EDTA capillary Tube, 50 Micro liters,
case of 100
Glove, latex disposable large, powdered, 100pcs
Glove, latex disposable medium, powdered, 100pcs
Glove, latex disposable small, powdered, 100pcs
BD Vacutainer needle 21 G, 1000
BD Vacutainerone use holders, 1000pcs
BD Vacutainer PLK2 E, or EDTA 5 ml, 1000pcs
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BD Vacutainer tubes, Cat plus or plain/red-top,
10ml, 1000 pcs
Pasteur pipette, non-sterile, 3ml, 500pcs
Biohazard bag,  610x760 mm, 100pcs
Cryobox for 1.8 ml tubes, 10X10 autoclavable, 1pcs
Cryogenic vials 1.8 ml size, 1800pcs
Lancets, 2000pkg
Contact purple lancet of 2000pcs
Pipette tips 1000 ul, 1000pcs, non-filtered Blue
Pipette tips 200 ul, 1000pcs, non-filtered, Yellow
Sharps container, 22.5 liter, 5 pk
Sodium hypcholorite, 1 liter
Test tube racks of 30 holes for 10ml plain tubes
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Tourniquet, 100 Pkg
Disposable syringes , 21G needle, 10ml size, 500pcs
Disposable syringes , 21G needle, 2ml size, 500pcs
Disposable syringes , 21G needle, 5ml size, 500pcs
Face masks, sterilizable, 50pcs
White apron, reusable plastic, medium 100 pack
White apron, reusable plastic, small 100 pack
Incenirator plastic bin
Rack wire poxy grid half size
Tests various
RPR syphilis test kits
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Pregnancy test kits - dipstick
Cryptococcal latex Ag test kits
Annex 6:Human Resource Questionnaire
Hello, My Name is Shimelis Endailalu. I am collecting Data for the costing of
antiretroviral therapy at Zewditu Hospital and here want to collect information about your
ART clinic’s human resource capacity. I would like to ask you few questions about your
staff as well as some questions pertaining to HIV/AIDS services. Please note that the
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information required was that of 2006. All information collected will be kept confidential
and will only be used for the intended purpose.
1. Name of the Health Facility______________________________________
2. Name of the respondent _______________________________________
3. Date of interview _____________________________________________
Staff type Total
number
Current monthly salary
Doctors
Nurses
Lab technicians
Pharmacists
Counselors
Social Workers
Data clerks
Thank you for participating in the survey!
Annex7: Work Plan
Thesis work plan and Time line
Sr. Technical Objective Activity Time line
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No
Jan Feb March April May June
1 Detailed description of
cost component of
delivering ART in the
public sector health
facility in Addis Ababa
1. Develop and agree on the
thesis proposal for a partial
fulfillment of the requirements
for the degree of Master of
Public Health
2. Refine data collection tools
and start the Data collection at
Zewditu Hospital
3. Data entry and  analysis
4.Data compilation and Report
writing
5. Submission of Draft report
6. Finalization and Defense of
thesis out comes
Annex 8: General cost
information for ARVs
Naïve Patients
Regimen Percentage Cost PPPM Cost PPPY
1 AZT/3TC/NVP 40.00% $20.50 $246.00
2 AZT/3TC/EFV 30.00% $21.92 $263.04
3 TDF/3TC/EFV 24.00% $32.46 $389.52
4 TDF/3TC/NVP 5.00% $23.44 $281.28
5 ABC/3TC/AZT 0.50% $37.03 $444.36
6 ABC/3TC/NVP 0.50% $33.97 $407.64
Weighted Average cost per patient per year $289.08
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For Experienced patients
Regimen Percentage Cost PPPM Cost PPPY
1 d4T/3TC/NVP 43.35% $7.40 $88.80
2 d4T/3TC/EFV 20.75% $16.42 $197.04
3 AZT/3TC/NVP 16.45% $20.50 $246.00
4 AZT/3TC/EFV 12.67% $21.92 $263.04
5 TDF/3TC/EFV 4.00% $32.46 $389.52
6 TDF/3TC/NVP 1.73% $23.44 $281.28
7 ABC/3TC/EFV 0.50% $42.99 $515.88
8 ABC/3TC/NVP 0.50% $33.97 $407.64
Weighted Average cost per patient per year $178.32
Regimen Percentage Cost PPPM Cost PPPY
1 AZT/3TC/NVP 17.28% $14.56
$
174.72
2 AZT/3TC/EFV 9.72% $23.57
$
282.84
3 TDF/3TC/EFV 1.80% $35.48
$
425.76
4 TDF/3TC/NVP 3.20% $25.74
$
308.88
5 ABC/3TC/EFV 0.36% $47.28
$
567.36
6 ABC/3TC/NVP 0.64% $37.54
$
450.48
7 d4T/3TC/NVP 42.88% $8.40
$
100.80
8 d4T/3TC/EFV 24.12% $17.95
$
215.40
Weighted Average cost per patient per year $242.88
Note: PPPY=Per Patient Per
Year Note: PPPM=Per Patient Per Month
Over All Cost of Antiretroviral drugs from the National quantification, from 2009-2014
Product Packaging 2009 2010 2011 2012 2013 2014 TOTAL
Abacavir 300MG/tab 60 24,118 34,486 40,068 42,858 44,937 45,083 186,467
Efavirenz 600MG/tab 30 1,028,492 1,593,526 1,897,754 2,049,819 2,163,097 2,194,877 8,732,689
Lamivudine 150MG/tab 60 322,222 633,250 800,715 884,420 946,775 984,595 3,587,382
Lamivudine-Stavudine
150+30MG/tab
60
357,860 357,860 357,860 357,860 357,860 328,038 1,789,299
Lamivudine-Stavudine-
Nevirapine 150+30+200MG/tab
60
747,625 747,625 747,625 747,625 747,625 685,323 3,738,125
Lamivudine-Zidovudine
150+300MG/tab
60
424,665 735,693 903,158 986,863 1,049,218 1,078,501 4,099,596
Lamivudine-Zidovudine-
Nevirapine
150+300+200MG/cotab
60
558,574 973,277 1,196,564 1,308,172 1,391,311 1,430,993 5,427,898
1Nevirapine 200MG/tab 60 84,872 144,629 176,804 192,887 204,867 210,220 804,058
Tenofovir disoproxil fumarate
300MG/tab
30 298,104 598,764 760,647 841,562 901,839 939,513 3,400,917
Cost
Product
Pack
Price
2009 2010 2011 2012 2013 2014 TOTAL
Abacavir 300MG/tab $32.21 $776,849 $1,110,789 $1,290,592 $1,380,464 $1,447,413 $1,452,113 $7,458,220
Efavirenz 600MG/tab $14.53 $14,945,433 $23,156,166 $27,577,024 $29,786,745 $31,432,830 $31,894,632 $158,792,830
Lamivudine 150MG/tab $3.56 $1,146,079 $2,252,343 $2,847,982 $3,145,706 $3,367,490 $3,502,008 $16,261,608
Lamivudine-Stavudine
150+30MG/tab
$4.68
$1,674,784 $1,674,784 $1,674,784 $1,674,784 $1,674,784 $1,535,218 $9,909,136
Lamivudine-Stavudine-
Nevirapine
$8.66
$6,472,937 $6,472,937 $6,472,937 $6,472,937 $6,472,937 $5,933,526 $38,298,212
2150+30+200MG/tab
Lamivudine-Zidovudine
150+300MG/tab
$11.12
$4,720,149 $8,177,223 $10,038,596 $10,968,984 $11,662,057 $11,987,540 $57,554,548
Lamivudine-Zidovudine-
Nevirapine
150+300+200MG/cotab
$23.99
$13,397,391 $23,344,060 $28,699,589 $31,376,495 $33,370,599 $34,322,359 $164,510,495
Nevirapine 200MG/tab $3.98 $337,619 $575,335 $703,327 $767,303 $814,960 $836,253 $4,034,798
Tenofovir disoproxil
fumarate 300MG/tab
$19.89
$5,929,289 $11,909,421 $15,129,270 $16,738,678 $17,937,572 $18,686,912 $86,331,142
Detailed Adult Second Line ARV Requirements by Pack and by Value
Product Packaging 2009 2010 2011 2012 2013 2014 TOTAL
Nevirapine 200MG/tab 60 223 1,244 4,334 8,923 14,762 21,598 51,084
3Zidovudine 300mg/ tab 60 11,901 29,653 68,712 117,224 170,561 226,183 624,234
Lamivudine 150MG/tab 60 20,285 68,449 131,906 191,009 244,263 291,882 947,793
Efavirenz 600MG/tab 30 273 1,546 5,433 11,307 18,908 27,953 65,419
Lamivudine-Stavudine
150+30MG/tab
60
775 744 616 510 423 350 3,418
Didanosine 250mg/cap 60 24,712 69,267 131,681 194,328 254,513 311,520 986,022
Didanosine 400mg/cap 30 6,970 19,537 37,141 54,810 71,786 87,865 278,109
Lopinavir/ritonavir,(200+50)/tab 120 55,425 125,176 185,759 247,405 307,113 364,047 1,284,925
Tenofovir 300mg/tab 30 25,319 73,298 135,696 193,577 245,490 291,688 965,068
Atazanavir/ritonavir,(300+100)/tab 120 0 44,929 150,088 255,412 356,542 452,357 1,259,328
Abacavir 300mg/tabs 60 19,110 78,908 168,799 260,855 350,716 436,963 1,315,350
Product
Pack
Price
2009 2010 2011 2012 2013 2014 TOTAL
4Nevirapine 200MG/tab $4.39 $978 $5,459 $19,016 $39,149 $64,768 $94,761 $224,132
Zidovudine 300mg/ tab $9.36 $111,396 $277,549 $643,145 $1,097,215 $1,596,449 $2,117,077 $5,842,832
Lamivudine 150MG/tab $3.51 $71,199 $240,256 $462,989 $670,441 $857,363 $1,024,507 $3,326,755
Efavirenz 600MG/tab $14.63 $3,986 $22,612 $79,453 $165,364 $276,528 $408,818 $956,760
Lamivudine-Stavudine
150+30MG/tab
$4.68
$3,625 $3,484 $2,885 $2,388 $1,978 $1,637 $15,996
Didanosine 250mg/cap $14.63 $361,409 $1,013,035 $1,925,841 $2,842,046 $3,722,257 $4,555,978 $14,420,567
Didanosine 400mg/cap $23.40 $163,098 $457,165 $869,097 $1,282,565 $1,679,788 $2,056,031 $6,507,743
Lopinavir/ritonavir,(200+50)/tab $53.62 $2,971,969 $6,712,057 $9,960,615 $13,266,141 $16,467,713 $19,520,593 $68,899,089
Tenofovir 300mg/tab $13.16 $333,258 $964,791 $1,786,099 $2,547,961 $3,231,261 $3,839,340 $12,702,710
Atazanavir/ritonavir,(300+100)/tab $36.07 $0 $1,620,637 $5,413,831 $9,212,988 $12,860,879 $16,316,999 $45,425,334
Abacavir 300mg/tabs $29.25 $558,975 $2,308,055 $4,937,358 $7,629,999 $10,258,447 $12,781,156 $38,473,989
